Cart
sales@molnova.com
GLPG2534
CAS No. 2095615-97-5
GLPG2534( —— )
Catalog No. M36623 CAS No. 2095615-97-5
GLPG2534 is an orally active, selective and potent IRAK4 inhibitor with anti-inflammatory activity. GLPG2534 inhibits human and mouse IRAK4 and could be used to study psoriasis and atopic dermatitis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 264 | In Stock |
|
| 10MG | 432 | In Stock |
|
| 25MG | 842 | In Stock |
|
| 50MG | 1349 | In Stock |
|
| 100MG | 2158 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGLPG2534
-
NoteResearch use only, not for human use.
-
Brief DescriptionGLPG2534 is an orally active, selective and potent IRAK4 inhibitor with anti-inflammatory activity. GLPG2534 inhibits human and mouse IRAK4 and could be used to study psoriasis and atopic dermatitis.
-
DescriptionGLPG2534 is an orally active and selective IRAK4 inhibitor, with IC50 values of 6.4 nM and 3.5 nM for human and mouse IRAK4. GLPG2534 can be used for the research of inflammatory skin diseases.
-
In Vitro——
-
In VivoAnimal Model:Psoriasis-like skin inflammation model, induced by IL-23 and IMQ Dosage:10 and 30 mg/kg Administration:p.o., b.i.d. 5 days Result:Reduced IL-23-induced expression of pathogenic cytokines such as Il17a (79%), Il22 (49%), Il1b (97%), and defensin Lcn2 (69%).
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetIRAK
-
RecptorIRAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2095615-97-5
-
Formula Weight424.45
-
Molecular FormulaC21H24N6O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (235.60 mM; Ultrasonic )
-
SMILESN#CC1=CN=C(C=C1)N2C=NC=3C=C(OCCOCCO)C(=NC32)NC4CCOCC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lavazais S, et al. IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases. Sci Transl Med. 2023 Feb 15;15(683):eabj3289. ?
molnova catalog
related products
-
Edecesertib
Edecesertib (GS-5718) is a selective, orally active IRAK-4 inhibitor with anti-inflammatory properties, applicable for the study of rheumatoid arthritis (RA) and lupus erythematosus (LE).
-
IRAK-1-4 Inhibitor I
IRAK-1-4 Inhibitor I is a potent, dual inhibitor of IRAK4 and IRAK1 with IC50 of 0.2 uM and 0.3 uM, respectively.
-
AS 2444697
A potent, selective, orally bioavailable IRAK-4 inhibitor that potently inhibits human and rat IRAK-4 activity with subnanomolar order.
